Rosella Spadi
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 4
- Oncology top 2%
- Colorectal Cancer Treatments and Studies 7
- Pancreatic and Hepatic Oncology Research 7
- Cancer Immunotherapy and Biomarkers 5
-
- Gastric Cancer Management and Outcomes 5
- Cancer Research top 10%
- Pathology and Forensic Medicine top 10%
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 4
-
- Chemotherapy-related skin toxicity 3
-
- Drug-Induced Adverse Reactions 2
Rosella Spadi
27 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 77
- Hepatology 324
- Oncology 1.1k
- Pulmonary and Respiratory Medicine 489
- Cancer Research 218
- Pathology and Forensic Medicine 193
Countries citing papers authored by Rosella Spadi
This map shows the geographic impact of Rosella Spadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosella Spadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosella Spadi more than expected).
Fields of papers citing papers by Rosella Spadi
This network shows the impact of papers produced by Rosella Spadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosella Spadi. The network helps show where Rosella Spadi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Rosella Spadi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 3 | |
| 4 | 2022 | 1 | |
| 5 | 2022 | 1 | |
| 6 | 2020 | 9 | |
| 7 | 2019 | 30 | |
| 8 | 2018 | 13 | |
| 9 | 2018 | 8 | |
| 10 | 2017 | 4 | |
| 11 | 2016 | 70 | |
| 12 | 2016 | 5 | |
| 13 | 2015 | 35 | |
| 14 | 2015 | 135 | |
| 15 | 2015 | 3 | |
| 16 | 2015 | 26 | |
| 17 | Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancerbreakdown → | 2014 | 720 |
| 18 | 2014 | 59 | |
| 19 | 2013 | 29 | |
| 20 | 2011 | 8 |
About Rosella Spadi
Rosella Spadi is a scholar working on Oncology, Hepatology and Dermatology, having authored 28 papers that have together received 1.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (7 papers), Pancreatic and Hepatic Oncology Research (7 papers), Cancer Immunotherapy and Biomarkers (5 papers), Gastric Cancer Management and Outcomes (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers), Chemotherapy-related skin toxicity (3 papers) and Drug-Induced Adverse Reactions (2 papers). The work is most often cited by research in Hepatology (324 citations), Oncology (1.1k citations) and Pulmonary and Respiratory Medicine (489 citations). Rosella Spadi has collaborated with scholars based in Italy, United States and Malaysia. Frequent co-authors include Alberto Zaniboni, Alfredo Falcone, Fotios Loupakis, Giuseppe Tonini, Chiara Cremolini, Sara Lonardi, Gianluca Masi, Luca Boni, Lisa Salvatore and Enrico Cortesi. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.